MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

Knippler CM, Saji M, Rajan N, Porter K, La Perle KMD, Ringel MD

DOI: 10.1530/erc-19-0188
Published: 2019 Aug
Container: Endocrine-related cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1530/erc-19-0188,
  title = {MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.},
  author = {Knippler CM and Saji M and Rajan N and Porter K and La Perle KMD and Ringel MD},
  year = {2019},
  journal = {Endocrine-related cancer},
  doi = {10.1530/erc-19-0188},
  url = {https://doi.org/10.1530/erc-19-0188}
}

RIS

TY  - JOUR
TI  - MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
AU  - Knippler CM
AU  - Saji M
AU  - Rajan N
AU  - Porter K
AU  - La Perle KMD
AU  - Ringel MD
PY  - 2019
JO  - Endocrine-related cancer
DO  - 10.1530/erc-19-0188
UR  - https://doi.org/10.1530/erc-19-0188
ER  -

APA

CM, K., M, S., N, R., K, P., KMD, L. P., & MD, R. (2019). MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.. Endocrine-related cancer. https://doi.org/10.1530/erc-19-0188

Source records

pubmed · retrieved 2026-09-26T09:10:13.026Z